(Reuters) - Genmab A/S and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of ...
-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab ...
Phase 3 innovaTV 301 confirmatory trial met its primary endpoint of improved overall survival (OS) at predetermined, independent interim analysis Trial results to be submitted for presentation at a ...
BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) today announced the upcoming presentation of detailed results from two pivotal Phase 3 studies at the ESMO Congress 2023. Results from the ...
TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer Cells New Monotherapy Approved for Use in a Cancer with Limited Treatment Options ...
On the verge of a $43 billion powerhouse merger with Pfizer, Seagen has two Presidential Symposium presentations at the European Society of Medical Oncology (ESMO) Congress in Madrid, further evidence ...
As the Federal Trade Commission (FTC) scrutinizes Pfizer’s $43 billion Seagen buyout, the antibody-drug conjugate (ADC) specialist has notched a phase 3 win that could broaden its cervical cancer ...
Sept 4 (Reuters) - Genmab A/S (GMAB.CO), opens new tab, and Seagen Inc (SGEN.O), opens new tab on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on ...
“TIVDAK is the only U.S. Food and Drug Administration-approved therapy in second-line recurrent or metastatic cervical cancer regardless of biomarker status, tumor histology and prior therapy,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback